Article
Medicine, Research & Experimental
Kinga Zelechowska-Matysiak, Evangelia-Alexandra Salvanou, Penelope Bouziotis, Tadeusz Budlewski, Aleksander Bilewicz, Agnieszka Majkowska-Pilip
Summary: In this article, we introduce a multimodal radiobioconjugate composed of doxorubicin, Au-198, and trastuzumab for targeted therapy of HER2+ cancers. The radiobioconjugate showed high affinity to HER2 receptors and induced cell cycle arrest and apoptosis in vitro. In spheroid models, it demonstrated dose-dependent additive and synergistic effects. Biodistribution and therapeutic efficacy studies in tumor-bearing mice exhibited promising results.
MOLECULAR PHARMACEUTICS
(2023)
Article
Nanoscience & Nanotechnology
Wenhua Zhan, Hanrui Li, Yingying Guo, Lu Yang, Liaojun Pang, Chaolin Zhang
Summary: Chemotherapy is limited by drug toxicity and side effects in treating breast cancer, but the combination of photothermal therapy with chemotherapy shows promise. A biodegradable mesoporous silica nanoparticle (bMSN NPs) system for loading doxorubicin (DOX) and IR780 has shown excellent therapeutic effects on breast cancer cells in vitro and in vivo.
Article
Materials Science, Characterization & Testing
Ruiling Xu, Junhui Sui, Mingda Zhao, Yuedi Yang, Lei Tong, Yongmei Liu, Yong Sun, Yujiang Fan, Jie Liang, Xingdong Zhang
Summary: This study developed trastuzumab functionalized nanoparticles for the treatment of HER-2 positive breast cancer cells. The results showed significant cell uptake and cytotoxic effect in HER-2 positive cells, while no differences were observed in HER-2 negative cells.
Article
Medicine, Research & Experimental
M. V. M. Novais, E. R. Gomes, M. C. Miranda, J. O. Silva, D. A. Gomes, F. C. Braga, R. M. Padua, M. C. Oliveira
Summary: Cancer is a major global public health problem, with current chemotherapy drug DOX limited by cardiotoxicity. To address this issue, research has developed drug-loaded liposomes to enhance the therapeutic effect in cancer treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Chemistry, Multidisciplinary
Jaeho Shin, Baksun Kim, Tyson W. Lager, Franklin Mejia, Ian Guldner, Clay Conner, Siyuan Zhang, Athanasia D. Panopoulos, Basar Bilgicer
Summary: This study describes the rational engineering of liposomal nanoparticles loaded with a doxorubicin prodrug to selectively target metastatic breast cancer cells in vivo. Glucose-regulated protein 78 (GRP78), which is typically localized in the endoplasmic reticulum, has been identified as a promising therapeutic target in certain cancers. The researchers optimized a nanoparticle formulation with a GRP78-binding peptide to selectively target an aggressive subpopulation of stem-like breast cancer cells expressing surface GRP78.
Article
Biochemistry & Molecular Biology
Federica Sola, Mariele Montanari, Mara Fiorani, Chiara Barattini, Caterina Ciacci, Sabrina Burattini, Daniele Lopez, Alfredo Ventola, Loris Zamai, Claudio Ortolani, Stefano Papa, Barbara Canonico
Summary: This study investigates the preferential mitochondrial targeting of fluorescent silica nanoparticles in myeloid cells and their conjugation with the anticancer drug doxorubicin. The functionalized nanoparticles show reduced cytotoxicity and specific ability to release extracellular vesicles involved in tumor progression. This research highlights the importance of modulating signaling pathways in cancer cells using targeted nanoparticles.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Nanoscience & Nanotechnology
Iris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, Juan F. F. Blandez, Vicente Candela-Noguera, Ana Lluch, Begona Bermejo, Felix Sancenon, Juan Miguel Cejalvo, Ramoin Martinez-Manez, Pilar Eroles
Summary: Despite advances in breast cancer treatment, it remains the leading cause of cancer-related death in women worldwide. In this study, a nanodevice using mesoporous silica nanoparticles for miR-200c-3p delivery was designed and validated. The nanodevice demonstrated biocompatibility, escape ability from endosomes/lysosomes, and inhibition of tumor progression, invasion, migration, and proliferation in vitro. In vivo experiments confirmed tumor targeting, effective miR-200c-3p delivery, therapeutic efficacy with reduced tumor size and lung metastasis, and no signs of toxicity. Overall, miR-200c-3p-loaded nanoparticles present a potential strategy for breast cancer therapy and safe tumor-targeted delivery of microRNAs.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Article
Nanoscience & Nanotechnology
Paolo Rainone, Antonella De Palma, Francesco Sudati, Valentina Roffia, Valentina Rigamonti, Lucia Salvioni, Miriam Colombo, Marilena Ripamonti, Antonello Enrico Spinelli, Davide Mazza, Pierluigi Mauri, Rosa Maria Moresco, Davide Prosperi, Sara Belloli
Summary: The study demonstrated the potential of using functionalized silica-based nanocarriers for theranostic treatment of HER2-positive breast cancer, showing promising results in terms of diagnostic specificity and treatment efficacy. The data obtained indicated that this system exhibited better tumor uptake and treatment efficacy compared to conventional chemotherapy drugs.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Pharmacology & Pharmacy
Ping Huang, Jia-huan Huang, Ya-bing Zheng, Wen-ming Cao, Xi-ying Shao, Jun-qing Chen, Yuan Huang, Guang-liang Li, K. Sharma, Huan-huan Zhou, Xiao-jia Wang, Hong-chuan Jin, Zhan-hong Chen
Summary: This study retrospectively collected clinical data of patients with HER2-positive eBC and found that the sequential use of PLD and trastuzumab showed a lower incidence of clinical cardiotoxicity compared to conventional treatment, presenting as asymptomatic decreased LVEF.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Sunil Kumar Dubey, Tanya Bhatt, Mukta Agrawal, Ranendra Narayan Saha, Swarnlata Saraf, Shailendra Saraf, Amit Alexander
Summary: Breast cancer, one of the most invasive cancers in women with high mortality rates, can potentially be targeted and treated more effectively using chitosan-based nanocarriers, which offer unique advantages in overcoming the limitations of current therapies. Research in this area has been focused on exploring novel techniques and improving targeted therapy for breast cancer, with promising results in recent years.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Multidisciplinary Sciences
Edward Seung, Zhen Xing, Lan Wu, Ercole Rao, Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil, Zhili Song, Bailin Zhang, Mikhail Levit, Gejing Deng, Andrew Hebert, Patrick Kirby, Aiqun Li, Emma-Jane Poulton, Rita Vicente, Audrey Garrigou, Peter Piepenhagen, Greg Ulinski, Michele Sanicola-Nadel, Dinesh S. Bangari, Huawei Qiu, Lily Pao, Dmitri Wiederschain, Ronnie Wei, Zhi-yong Yang, Gary J. Nabel
Summary: A trispecific antibody targeting HER2 and T cells can inhibit breast cancer cell proliferation by stimulating CD4 T cells, and induce tumor regression in a humanized mouse model.
Article
Chemistry, Multidisciplinary
Sadaf Hameed, Pravin Bhattarai, Zhuoran Gong, Xiaolong Liang, Xiuli Yue, Zhifei Dai
Summary: This study focuses on the synthesis of ultra-small hydrophilic porphyrin-based silica nanoparticles to enhance the treatment outcomes of cancer via photodynamic therapy. These nanoparticles show excellent solubility in water, enhanced tumor accumulation, and imaging-guided therapeutic abilities. They also exhibit biocompatibility and stability in physiological solutions.
NANOSCALE ADVANCES
(2022)
Article
Oncology
Sanja Loeb, Eva Linsmeier, Saskia-Laureen Herbert, Tanja Schlaiss, Matthias Kiesel, Joerg Wischhusen, Jessica Salmen, Peter Kranke, Anne Quenzer, Florian Kurz, Claire Weiss, Elena Gerhard-Hartmann, Achim Woeckel, Joachim Diessner
Summary: The purpose of this study was to investigate the changes in HER2 subtypes between primary breast cancer and recurrent disease. The results showed that HER2 expression increased during the progression of the disease. This information is important for the development of therapeutic options for breast cancer patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Yuheng Pang, Runze Shi, Liujia Chan, Yu Lu, Di Zhu, Tong Liu, Meisi Yan, Yuji Wang, Wenjing Wang
Summary: This study investigated the synergistic potential of Vorinostat (SAHA) and Doxorubicin (DOX) in combination against triple-negative breast cancer (TNBC). The results showed that the combination of these two drugs could enhance the inhibitory effect on cancer cell proliferation, alter cell mitotic phase, and regulate the immune microenvironment within tumors. This presents a promising avenue for innovative combination chemotherapy in the context of TNBC.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Biotechnology & Applied Microbiology
Quanyuan Wan, Zihua Zeng, Jianjun Qi, Zhenghu Chen, Xiaohui Liu, Youli Zu
Summary: The study demonstrates the effectiveness of targeted chemotherapy for triple-negative breast cancer using a DNA nanoparticle to deliver doxorubicin to cancer cells, showing promising results in vitro and in animal experiments while potentially reducing side effects for patients.
